104
Participants
Start Date
December 21, 2020
Primary Completion Date
August 18, 2021
Study Completion Date
August 18, 2021
PF-07038124 ointment
PF-07038124 ointment at 0.01% with QD dosing for 6 weeks
Vehicle ointment
Vehicle ointment with QD dosing for 6 weeks
Australian Clinical Research Network, Maroubra
Emeritus Research, Camberwell
M3 Wake Research, Inc., Raleigh
Clinical Neuroscience Solutions, Orlando
Moonshine Research Center, Inc., Doral
Center for Clinical Studies, Tampa
Olympian Clinical Research, Clearwater
Renaissance Research and Medical Group, Cape Coral
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare, Memphis
The Indiana Clinical Trials Center, PC, Plainfield
Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Henry Ford Medical Center, New Center One, Detroit
Center for Clinical Studies, Houston
studies in Dermatology, LLC, Cypress
Center for Clinical Studies, LTD. LLP, Webster
First OC Dermatology, Fountain Valley
Oregon Dermatology and Research Center, Portland
Dermatrials Research Inc., Hamilton
Lynderm Research Inc., Markham
DermEdge Research, Mississauga
Innovaderm Research Inc., Montreal
Centre de Recherche Dermatologique du Quebec metropolitain, Québec
NZOZ Specjalistyczny Osrodek Dermatologiczny DERMAL, Bialystok
Mazowieckie Centrum Badań Klinicznych, Grodzisk Mazowiecki
Centrum Medyczne Angelius Provita, Katowice
Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna, Lodz
Dermedic Jacek Zdybski, Ostrowiec Świętokrzyski
Kliniczny Szpital Wojewódzki nr 1 im. F. Chopina w Rzeszowie, Rzeszów
ETG Warszawa, Warsaw
Lead Sponsor
Pfizer
INDUSTRY